• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/8/21 10:15:35 AM ET
    $ALXN
    Major Pharmaceuticals
    Health Care
    Get the next $ALXN alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 23 ALEXION PHARMACEUTICALS INC COMMON STOCK Cusip #015351109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #015351109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 987,470 Item 6: 0 Item 7: 6,329,881 Item 8: 0 Item 9: 6,329,881 Item 11: 2.894% Item 12: HC Cusip #015351109 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 6,329,881 Item 8: 0 Item 9: 6,329,881 Item 11: 2.894% Item 12: IN Item 1(a). Name of Issuer: ALEXION PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 121 Seaport Boulevard Boston, MA 02210 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 015351109 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 6,329,881 (b) Percent of Class: 2.894% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 987,470 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 6,329,881 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ALEXION PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of ALEXION PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 5, 2021 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Crosby Advisors LLC N/A FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC IA Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 5, 2021, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ALEXION PHARMACEUTICALS INC at December 31, 2020. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.
    Get the next $ALXN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALXN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALXN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Moderna Set to Join S&P 500

      NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 21, 2021 S&P 500 Addition Moderna MRNA Health Care S&P 500 Deletion Alexion Pharmaceuticals ALXN Health Care For more information about S&P Dow Jones Indices, please

      7/15/21 7:01:00 PM ET
      $SPGI
      $ALXN
      $AZN
      $MRNA
      Finance: Consumer Services
      Finance
      Major Pharmaceuticals
      Health Care
    • Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

      – Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling efficacy as early as Week 1, sustained for 52 weeks – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS® (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG). The study met, with high statistical significance, its primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score, a patient-reported assessment, at Week 26, and for the s

      7/15/21 4:05:00 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021

      NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Honeywell International Inc. (NASDAQ:HON), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX), the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) and the NASDAQ-100 Ex-Technology Index (NASDAQ:NDXX) prior to market open on Wednesday, July 21, 2021. Honeywell International Inc. will replace Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the NASDAQ-100 Index®, the NASDAQ-100 Equal Weighted Index and the NASDAQ-100 Ex-Technology Index. For more information about the company, go to https://www.honeywell.com/ . About Nasdaq Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital ma

      7/14/21 8:00:00 PM ET
      $ALXN
      $NDAQ
      $HON
      Major Pharmaceuticals
      Health Care
      Investment Bankers/Brokers/Service
      Finance

    $ALXN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Alexion Pharmaceuticals, Inc.

      15-12G - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      8/2/21 9:02:07 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.

      EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      7/26/21 12:15:08 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.

      EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      7/26/21 12:15:53 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    Leadership Updates

    Live Leadership Updates

    See more
    • Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,

      12/1/20 4:30:00 PM ET
      $LLY
      $DRNA
      $NVO
      $ALXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $ALXN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alexion Pharma upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Alexion Pharma from Perform to Outperform and set a new price target of $205.00

      5/5/21 6:41:15 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Credit Suisse resumed coverage on Alexion Pharma with a new price target

      Credit Suisse resumed coverage of Alexion Pharma with a rating of Neutral and set a new price target of $190.00

      4/26/21 8:53:18 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Alexion Pharma downgraded by SVB Leerink

      SVB Leerink downgraded Alexion Pharma from Outperform to Mkt Perform

      3/23/21 7:28:52 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/16/21 12:23:41 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/12/21 6:51:47 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/10/21 10:30:29 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: COUGHLIN CHRISTOPHER J returned 42,347 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:54:11 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: FRIEDMAN PAUL A returned 12,840 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:51:08 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: SARIN ARADHANA returned 120,253 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:52:30 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care